Report Detail

Other Recessive Dystrophic Epidermolysis (RDEB)- Pipeline Insight, 2019

  • RnM3781340
  • |
  • 25 September, 2019
  • |
  • Global
  • |
  • 60 Pages
  • |
  • DelveInsight
  • |
  • Other

"Recessive Dystrophic Epidermolysis (RDEB)- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Recessive Dystrophic Epidermolysis pipeline landscape is provided which includes the disease overview and Recessive Dystrophic Epidermolysis treatment guidelines. The assessment part of the report embraces, in depth Recessive Dystrophic Epidermolysis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Recessive Dystrophic Epidermolysis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Recessive Dystrophic Epidermolysis Understanding
Recessive dystrophic epidermolysis bullosa is an inherited blistering skin disorder caused by mutations in the COL7A1 gene-encoding type VII collagen (Col7), the major component of anchoring fibrils at the dermal–epidermal junction. Individuals with RDEB develop painful blisters and mucosal erosions. RDEB can be further classified as Severe Generalised and Generalised Intermediate. Severe Generalized - In this form, the skin is extremely fragile, often with extensive blistering and wounds. There is usually no collagen VII present. Wounds tend to heal with a scar that can lead to contractures and impaired movement, particularly affecting the hands. Generalised Intermediate– In this form, there is usually some collagen VII present in the skin. There is a tendency for the skin to blister and for wounds to develop, the extent being dependent on the amount of collagen VII present. The lining of the mouth and esophagus are usually fragile. The hands will be scarred with some contractures but the severity is less than those with RDEB-SG.
Recessive Dystrophic Epidermolysis Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Recessive Dystrophic Epidermolysis targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Recessive Dystrophic Epidermolysis pipeline report covers 10+ companies. Some of the key players include Fibrocell Science (FCX 007), Abeona Therapeutics (EB 101) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Recessive Dystrophic Epidermolysis Analytical Perspective by DelveInsight
• In-depth Recessive Dystrophic Epidermolysis Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
• Recessive Dystrophic Epidermolysis Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
• The Recessive Dystrophic Epidermolysis report provides an overview of therapeutic pipeline activity for Recessive Dystrophic Epidermolysis across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Recessive Dystrophic Epidermolysis therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
• Detailed Recessive Dystrophic Epidermolysis Research and Development progress and trial details, results wherever available, are also included in the pipeline study
• Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Recessive Dystrophic Epidermolysis
Reasons to Buy
• Establish a comprehensive understanding of the current pipeline scenario across Recessive Dystrophic Epidermolysis to formulate effective R&D strategies
• Assess challenges and opportunities that influence Recessive Dystrophic Epidermolysis R&D
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Get in detail information of each product with updated information on each project along with key milestones
• Devise Recessive Dystrophic Epidermolysis in licensing and out licensing strategies by identifying prospective partners with progressing projects for Recessive Dystrophic Epidermolysis to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs


Table 1. Recessive Dystrophic Epidermolysis Diagnostic Guidelines

    Table 2. Treatment Guidelines

      Table 3. Assessment Summary

        Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis

          Table 5. Recessive Dystrophic Epidermolysis Acquisition Analysis

            Table 6. Assessment by Phase of Development

              Table 7. Assessment by Product Type (Mono / Combination)

                Table 8. Assessment by Stage and Product Type

                  Table 9. Assessment by Route of Administration

                    Table 10. Assessment by Stage and Route of Administration

                      Table 11. Assessment by Molecule Type

                        Table 12. Assessment by Stage and Molecule Type

                          Table 13. Assessment by MOA

                            Table 14. Assessment by Stage and MOA

                              Table 15. Late Stage Products (Phase-III)

                                Table 16. Mid Stage Products (Phase-II)

                                  Table 17. Early Stage Products (Phase-I)

                                    Table 18. Pre-clinical and Discovery Stage Products

                                      Table 19. Inactive Products

                                        Table 20. Dormant Products

                                          Table 21. Discontinued Products

                                          Summary:
                                          Get latest Market Research Reports on Recessive Dystrophic Epidermolysis (RDEB). Industry analysis & Market Report on Recessive Dystrophic Epidermolysis (RDEB) is a syndicated market report, published as Recessive Dystrophic Epidermolysis (RDEB)- Pipeline Insight, 2019. It is complete Research Study and Industry Analysis of Recessive Dystrophic Epidermolysis (RDEB) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                          Last updated on

                                          REPORT YOU MIGHT BE INTERESTED

                                          Purchase this Report

                                          $1,250.00
                                          $2,500.00
                                          $3,750.00
                                          990.00
                                          1,980.00
                                          2,970.00
                                          1,157.50
                                          2,315.00
                                          3,472.50
                                          189,187.50
                                          378,375.00
                                          567,562.50
                                          104,250.00
                                          208,500.00
                                          312,750.00
                                          Credit card Logo

                                          Related Reports


                                          Reason to Buy

                                          Request for Sample of this report